Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022

Monday, November 13, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

"Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy.

LONDON, Nov. 13, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5193339As per

report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment of cancer and more than 45 CDK inhibitors are in various phases of clinical pipeline."Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report highlights:• Selectivity & Working Mechanism of a Cancer CDKs Inhibitor• Recent Advances in the CDKs Related Cancer Therapy• Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline• Market Opportunity Assessment: More Than US$ 20 Billion (2022)• Price Analysis of Cancer CDKs Inhibitors: • Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)The Cyclin Dependent Kinase (CDK) Inhibitors have recently emerged as one of the most promising therapeutics in the cancer pharmaceuticals segment. The progress in the scientific and technical knowledge of how the cell cycle works, pathways involved in normal and tumorous cells and the role of cyclin in tumor cell formation (Tumorigenesis) has led to an excellent boost in the research and development of special molecules or inhibitors which can prevent tumorigenic processes in effected cells.Cyclin Dependent Kinase (CDK) Inhibitors are considered as promising and immensely effective targeted therapy of the future as it aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body. In addition, it has opened up multiple opportunities and avenues for the life sciences industry to work upon due to the vast diversity and variations seen in the CDK pathways and their specific role and response in various types of tumors, thus suggesting the need of different types of inhibitors for different cancer therapies.Currently, Pfizer's Ibrance is the only successfully market drug that has shown impressive growth in within two years of its introduction into the cancer therapy segment. Ibrance or Palbociclib first received an accelerated approval in February 2015, becoming the first CDKs inhibitor to receive approval for breast cancer therapy. In just two years Ibrance has shown excellent growth with time which is sure to make Ibrance the dominant CDKs inhibitor in the breast cancer therapy segment.The recent advances in the discovery of newer cyclin pathways and their inhibitors have opened up new avenues in the CDKs therapy market. Multiple companies are now currently working on various therapeutics that have shown some kind of novel response in stopping or inhibiting the cell cycle. While it is obvious that Pfizer's Ibrance is currently the most effective drug in breast cancer tumor management, it is expected that Eli Lilly and Novartis are currently working on much better therapeutic having higher overall efficacy than the Ibrance.A strong clinical pipeline presents an encouraging scenario regarding the future of a particular therapeutic like the CDK inhibitor. The intense research and development in the CDK inhibitor segment has led to many of these newly discovered compounds showing excellent results in various phase of the clinical trials. While very few CDKs have come out of the clinical pipeline and showed excellent commercial success, many of the inhibitors are anticipated to be a blockbuster drug once they come out of the clinical pipeline.With the advancement in science and further knowledge about the technical know-how of the cyclin dependent kinase and cell cycle, the ability and potential of CDKs inhibitor as cancer therapeutic is bound to improve. Previous success of approved CDKs inhibitors like Ibrance has shown the immense market potential of the CDKs inhibitor market which largely remains untapped, especially in the developing countries which are bound to show an increased demand for effective cancer therapeutic like the CDKs in the future.Download the full report: https://www.reportbuyer.com/product/5193339 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com  For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected]  Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/global-cancer-cdk-inhibitors-market--clinical-pipeline-outlook-2022-300554650.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store